Izotropic Corp. · CSE:IZO
Izotropic — Investor Presentation (December 2021)
28 slides from Izotropic's investor presentation, December 2021
Slide 1: Izotropic Corporation Investor Presentation
Gy ZOTR Pl CORPORATION INVESTOR PRESENTATION Gizoview
Slide 2: Izotropic Overview
IZOTROPIC OVERVIEW The only publicly traded company commercializing a dedicated breast CT im for the more accurate detection and diagnosis of breast cancers. BREAST CT EVOLUTION GROWING MARKET REGULATORY ¢ $20M spent on R&D to date via ¢ Breast imaging market growing from « Patient and payor dema go
Slide 3: 5th Generation Device
5TH GENERATION DEVICE First device for commercialization Proof of Concept Units by Dr. John M. Boone at UC Davis Four successive laboratory prototypes ¢ Over 600 patients imaged in a clinical study validating the technology ¢ Second ongoing clinical study with 400 patients underway IzoView for Comme
Slide 4: 2021 Best New Radiology Device Award Semifinalist
2021 BEST NEW RADIOLOGY DEVICE AWARD SEMIFINALIST Izotropic's IzoView Breast CT System Auntminnie.com, a leading radiology news website, has recognized |zotropic's IzoView Breast CT System in the Best New Radiology Device category in September 2021. AuntMinnie.com THE BEST OF RADIOLOGY SEMIFINALIST
Slide 5: Licensed Technology & Intellectual Property
LICENSED TECHNOLOGY & INTELLECTUAL PROPERTY GLOBAL LICENSING RIGHTS ¢ Exclusive worldwide licensing rights to Breast CT through an agreement with The Regents of The University of California * Developed over 20 years by principal technology founder and company director Dr. John M. Boone * Commerciali
Slide 6: True 3D Breast CT
TRUE 3D BREAST CT © IZOVIEW BREAST CT CSE: 1ZO OTCQB: IZOZF IMAGING IzoView produces high resolution breast images in true 3D and is ideal for imaging patients with dense breast tissue. A single 10 second scan acquires approximately 500 images, without painful breast compression or continual technic
Slide 7: Breast Cancer Is Now the Most Common Form
BREAST CANCER IS NOW THE MOST COMMON FORM U.S. Breast Cancer Landscape Facts. 41M BREASTS SCANS IN 2019 280K NEW BREAST CANCER CASES ¢ Screening mammography misses 1/5 cancers 1 in 8 women will be diagnosed with breast * >8,500 MSQA Certified imaging centers and cancer in their lifetime, 1 in 39 wil
Slide 8: Diagnostic Mammography Challenges
DIAGNOSTIC MAMMOGRAPHY CHALLENGES Limitations of the current standard of care. CONTINUAL BREAST COMPRESSION * Technician manipulation of the breast for multiple imaging views * 46% of patient non-compliance is due to pain * Concerns with breast implants (ie. discomfort and rupture) REQUIRES TECHNICA
Slide 9: Digital Breast Tomosynthesis
DIGITAL BREAST TOMOSYNTHESIS Latest improvement to the standard of care. Mammography machine pictured Tomosynthesis design similar The limitations of diagnostic mammography remain. Digital breast tomosynthesis adds 15- 50 degrees of image acquisition range (depending on the model of machine) which i
Slide 10: IzoView Breast CT
IZOVIEW BREAST CT A whole new experience for patients, radiologists and providers. NO BREAST COMPRESSION Natural breast orientation preserved, no pain or discomfort, very comfortable face down view, excellent visualization with contrast PATIENT EMPOWERMENT Patient places own breast in imaging cup, n
Slide 11: Solving an Unmet Need
LW) SOLVING AN UNMET NEED eed) Image Acquisition Matters. ru: ° Mammography Tomosynthesis WZ IZOVIEW o° 15° - 50° 360° 2D Image 2.5D Image True 3D, 500 slices 1 of the image slices CSE: 1ZO OTCQB: IZOZF BREAST CT IMAGING - 11
Slide 12: Solving an Unmet Need
SOLVING AN UNMET NEED ‘e Images below are of the same breast. Mammography Tomosynthesis WY 2D Image 2.5D Image
Slide 13: Clinical Studies
CLINICAL STUDIES nee") INITIAL CLINICAL STUDY DESIGN FOLLOW-ON CLINICAL STUDIES To expedite patient and provider access to IzoView, the Platform applications will be validated in follow-on clinical initial clinical study will demonstrate superior studies including breast screening in radiology, trea
Slide 14: IzoView Platform Uses
IZOVIEW PLATFORM USES Making Breast CT an indispensable tool for improving the outcomes of br. STEPS TO TREATMENT: PLATFORM PRODUCTS: SALES MODELS: CSE: IZO OTCQB: IZOZF y , SCREENING DIAGNOSTIC BIOPSY TREATMENT NEW INDICATIONS /NITIAL REGULATORY NEW ACCESSORIES FOCUS <_< ONE TIME, RENTAL, ONE TIME
Slide 15: Market Acceptance
MARKET ACCEPTANCE Customers are asking for IZOVIEW today. PATIENTS Breast CT can create a better experience for wider patient adoption DOCTORS 3D visualization capabilities and the use of contrast expands use cases HOSPITALS & CLINICS Can improve throughput and attract more patients INSURANCE PAYORS
Slide 16: Historical Milestones
IN LYN HISTORICAL MILESTONES ew 3S o > & SL L& So 2 S oe OS a ics a & wg F gs of & & S S os s a e & RY Sy? aoe & ~ & & ww eo oe xe Ks o s&s RG Ss 4 g “xy a & < & eee Ee Ra & ee aS wv “3 ee SSF Ws aS S ye “ss es Fo Ss = SS s PRS ge Fs Ss ~~ aS S SF FP FX KS SF CS Sse <S * w s we & e < ~Y cia 2018 Q12
Slide 17: Projected Timelines
PROJECTED TIMELINES S G Implementation of 3D imaging reconstruction software begins y, Mechanical and electrical design completed G Clinical trial design finalized + Industrial design completed + Fabrication of IzoView begins for the initial device build (underway) * Clinical trial site selection be
Slide 18: Broad Engagement Preparing for Market
BROAD ENGAGEMENT PREPARING FOR MARKET Near-term catalysts across multiple workstreams. DEVELOPMENT ¢ Al software modules and hardware accessories to expand IzoView platform ¢ Partnerships to accelerate product development: Deep-learning machine algorithms with Johns Hopkins University School of Medi
Slide 19: Directors & Management
DIRECTORS & MANAGEMENT JOHN M. BOONE, PHD Founder & Director JOHN MCGRAW, PHD Director & CEO Executive in imaging, diagnostic service, and medical device public companies Medical Physicist, Professor, global speaker, text book author, ICRU Commissioner JODY BELLEFLEUR CPA, CGA, CFO 25 years' experei
Slide 20: Dr. John Boone
¢ Editor- In-Chief of Medical Physics, the official journal of the American Association of Physicists DR. JOHN BOONE in Medicine (AAPM) Principal Founder of Breast CT Technology & Director ¢ Commissioner of the International Commission of Radiation Units & Measurements (ICRU) * Recipient of the Amer
Slide 21: Dr. John McGraw
DR. JOHN MCGRAW Chief Executive Officer "High resolution breast imaging is critical to identifying malignancies as early as possible. Izotropic’s Breast CT has the opportunity to offer patients, with or without dense breasts, a single rapid scan for breast cancer detection in complete comfort and di
Slide 22: Dr. Younes Achkire
DR. YOUNES ACHKIRE Executive Vice President of Product Engineering "As a medtech engineering executive with decades of experience, | know the potential Izoview has to disrupt the world of breast imaging. With my expertise in developing high precision equipment, | will engineer novelties in Izoview t
Slide 23: Dr. Andrew Hernandez
DR. ANDREW HERNANDEZ Head of Imaging Technology ¢ Ph.D. from UC Davis followed by 8 years working on the design, development, and optimization of breast CT under the "The IzoView breast CT system will fully harness the capabilities of advanced x-ray imaging hardware and is designed to provide except
Slide 24: Medical & Scientific Advisors
MEDICAL & SCIENTIFIC ADVISORS Internationally Recognized Specialists that played vital roles in DR. MARTIN YAFFE PHD DR. KAREN LINDFORS MD, MPH, FACR Expert in the field of breast cancer screening and Drove the development of digital mammography, Member of The information co! Cioran meee mene and do
Slide 25: Market Capitalization
MARKET CAPITALIZATION HY December 14, 2021 52 WEEK RANGE - CSE: CAD $0.66 - 1.56 : 52 WEEK RANGE - OTC: US $0.53 - $1.31 52 WEEK RANGE -FSE: EUR $0.15 - $1.02 COMMON SHARES ISSUED - BASIC: 43,227,459 0.75 WARRANTS: 5,520,000 @ $0.20 WARRANTS: 6,356,100 @ $0.75 WARRANTS: 1,896,679 @ $1.50 Oe BROKER W
Slide 26: Legal
LEGAL SECURITIES COUNSEL: CLARK WILSON LLP https://www.cwilson.com TRUST AGENT: ODYSSEY TRUST https://odysseytrust.com U.S. PATENT COUNSEL: VENABLE LLP https://www.venable.com REGULATORY COUNSEL: BROOKE CONSULTING LLC https://www.brooke-consulting.com CSE: 1ZO OTCQB: IZOZF BREAST CT IMAGING - 26
Slide 27: Disclaimer
DISCLAIMER This document may contain statements that are “Forward-Looking Statements,” which are based upon the current estimates, assumptions, projections and expectations of the company’s management, business, and its knowledge of the relevant market and economic environment in which it operates.
Slide 28: Investor Relations
INVESTOR RELATIONS: IR@izocorp.com 1-833-IZOCORP James Berrard ext.1 Tyler Muir ext.2 GENERAL INQUIRIES info@izocorp.com izocorp.com 1-833-IZOCORP ext. 3 Waizotroric Eaeizotropic ff eizorropic BREAST CT IMAGING - 28